Regulatory product record
RHEUMOCAM 1.5MG/ML ORAL SUSPENSION FOR DOGS
Product identity, ingredients and source provenance from the regulatory catalogue. Linked clinical evidence has a separate review status.
Owner information handout
Plain-language medication information to review with the owner. Open the handout to print it or download a PDF.
Product identity
- Brand name
- RHEUMOCAM 1.5MG/ML ORAL SUSPENSION FOR DOGS
- DIN
- 02389932
- DPD drug code
- 87540
- Regulatory category
- APPROVED_VET_DRUG
- Market status
- MARKETED
- Route(s)
- ORAL
- Pharmaceutical form(s)
- SUSPENSION
- Ingredients
- MELOXICAM (1.5 MG)
- Species (DPD record)
- DOGS
- Company
- CHANELLE PHARMACEUTICALS MANUFACTURING LIMITED (DIN owner)
Source and provenance
- Source dataset
- health_canada_dpd_marketed
- Source snapshot date
- Not available in this source
- Source record key
- 87540
- Archive fingerprint (SHA-256)
- 85cc3ce208af3aa57018c3d14d83f90220c436baef7455384b6d48d9774e1c88
Linked clinical reference
Clinical entries are linked through the active molecule. Check their species, formulation, source and review status separately from this product record.
Clinical evidence
Pending clinical review (PROPOSED)Rule-based (RULE_BASED)— applies to the facts and dose entries in this species selection; individual source records retain their own status.
Indications5
OA pain/inflammation (chronic)
DogOn-label (ON_LABEL)1 source record · View provenance
- Dog · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Indications table · Not applicable · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Original excerpt: OA pain/inflammation (chronic) — Authorized
- Dog · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Indications table · Not applicable · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Single-dose post-op pain (ovariohysterectomy, orthopedic, castration)
CatOn-label (ON_LABEL)1 source record · View provenance
- Cat · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Indications table · Not applicable · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Original excerpt: Single-dose post-op pain (ovariohysterectomy, orthopedic, castration) — Authorized (FDA, single SC dose)
- Cat · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Indications table · Not applicable · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Chronic low-dose use for OA/CKD pain
CatExtra-label (EXTRA_LABEL)1 source record · View provenance
- Cat · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Indications table · Not applicable · Extra-label (EXTRA_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Original excerpt: Chronic low-dose use for OA/CKD pain — Extra-label in US (licensed long-term in some other countries)
- Cat · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Indications table · Not applicable · Extra-label (EXTRA_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Meloxicam oral suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
Species not recordedOn-label (ON_LABEL)United States1 source record · View provenance
- Species not recorded · SPL section 34067-9 (INDICATIONS & USAGE SECTION) · United States · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
OstiLox (meloxicam) Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
DogOn-label (ON_LABEL)United States1 source record · View provenance
- Dog · SPL section 34067-9 (INDICATIONS & USAGE SECTION) · United States · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Dose regimens7
This calculator performs arithmetic only on the sourced dosing field shown for each result — it does not verify the field's accuracy, does not select which field to use for a patient, and does not replace a veterinarian's order. Not for clinical use. Confirm every result against the primary source before dispensing.
Select a species above to calculate a dose.
Adverse effects207
GI (vomiting, diarrhea, ulceration) — Most common
DogCatNot applicable (NOT_APPLICABLE)2 source records · View provenance
- Dog · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Side Effects / Adverse Effects table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
- Cat · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Side Effects / Adverse Effects table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Renal injury — Reported at ≥0.3–0.5 mg/kg and higher (dog); with repeated/dehydrated dosing (cat)
DogCatNot applicable (NOT_APPLICABLE)2 source records · View provenance
- Dog · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Side Effects / Adverse Effects table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
- Cat · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Side Effects / Adverse Effects table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Elevated liver enzymes, pruritus, azotemia — Post-approval reports
DogNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Dog · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Side Effects / Adverse Effects table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Field safety was evaluated in 306 dogs. Based on the results of two studies, GI abnormalities (vomiting,soft stools, diarrhea, and inappetence) were the most common adverse reactions associated with the administration ofmeloxicam. The following table lists adverse reactions and the numbers of dogs that experienced them during the studies.Dogs may have experienced more than one episode of the adverse reaction during the study. In foreign suspected adverse drug reaction (SADR) reporting over a 9 year period, incidences of adverse reactions related tomeloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog),nursing puppy lethargy (1 dog), and pyoderma (1 dog). Adverse Reactions Observed During Two Field Studies Clinical Observation Meloxicam (n=157) Placebo (n=149) Vomiting 40 23 Diarrhea/Soft Stool 19 11 Bloody Stool 1 0 Inappetence 5 1 Bleeding gums after dental procedure 1 0 Lethargy/Swollen Carpus 1 0 Epiphora 1 0
DogOn-label (ON_LABEL)United States1 source record · View provenance
- Dog · SPL section 34084-4 (ADVERSE REACTIONS SECTION) · United States · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Field safety was evaluated in 306 dogs. Based on the results of two studies, GI abnormalities (vomiting, soft stools, diarrhea, and inappetance) were the most common adverse reactions associated with the administration of meloxicam. The following table lists adverse reactions and the numbers of dogs that experienced them during the studies. Dogs may have experienced more than one episode of the adverse reaction during the study. In foreign suspected adverse drug reaction (SADR) reporting over a 9 year period, incidences of adverse reactions related to meloxicam administration included: auto-immune hemolytic anemia (1 dog), thrombocytopenia (1 dog), polyarthritis (1 dog), nursing puppy lethargy (1 dog), and pyoderma (1 dog). Adverse Reactions Observed During Two Field Studies Clinical Observation Meloxicam(n=157) Placebo(n=149) Vomiting 40 23 Diarrhea/Soft Stool 19 11 Bloody Stool 1 0 Inappetance 5 1 Bleeding gums after dental procedure 1 0 Lethargy/Swollen Carpus 1 0 Epiphora 1 0
Species not recordedOn-label (ON_LABEL)United States1 source record · View provenance
- Species not recorded · SPL section 34084-4 (ADVERSE REACTIONS SECTION) · United States · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
These are counts of spontaneously reported events, not proven adverse effects, causal relationships, or incidence rates.
Bars compare report counts within each species; they do not show incidence.
More reportsFewer reportsDog
- Vomiting2,071 reports
- Anorexia1,257 reports
- Diarrhoea1,041 reports
- Depression768 reports
- Elevated blood urea nitrogen (BUN)688 reports
- Lethargy (see also Central nervous system depression in 'Neurological')621 reports
- Death615 reports
- Death by euthanasia598 reports
- Elevated creatinine537 reports
- Elevated serum alkaline phosphatase (SAP)512 reports
- Elevated alanine aminotransferase (ALT)503 reports
- Bloody diarrhoea444 reports
Cat
- Anorexia1,300 reports
- Elevated creatinine1,253 reports
- Elevated blood urea nitrogen (BUN)1,219 reports
- Vomiting1,006 reports
- Depression896 reports
- Renal failure752 reports
- Hyperphosphataemia560 reports
- Azotaemia509 reports
- Death by euthanasia432 reports
- Death420 reports
- Weight loss325 reports
- Dehydration299 reports
Monitoring1
Clinical efficacy, adverse effects; renal + hepatic function if chronic use (esp. cats)
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Monitoring Parameters · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Contraindications4
Hypersensitivity; repeated dosing in cats — FDA black-box-style warning: associated with acute renal failure and death
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Contraindications & Warnings table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. See Contraindications, Warnings, and Precautions for detailed information.
DogOn-label (ON_LABEL)United States1 source record · View provenance
- Dog · SPL section 34066-1 (BOXED WARNING SECTION) · United States · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Contraindications Warnings Precautions Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. See,, andfor detailed information.
Species not recordedOn-label (ON_LABEL)United States1 source record · View provenance
- Species not recorded · SPL section 34066-1 (BOXED WARNING SECTION) · United States · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Do not use Meloxicam oral suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats. Dogs with known hypersensitivity to meloxicam should not receive Meloxicam oral suspension. Shake bottle well. Push down and unscrew bottle top. Attach the dosing syringe to the bottle by gently pushing onto the top of the bottle. Turn the bottle/syringe upside down. Pull the plunger out until the medication level corresponds to the dog's body weight in pounds. Turn the bottle right way up and with a twisting movement separate the dosing syringe from the bottle. Push the plunger to empty the contents of the syringe.
Species not recordedOn-label (ON_LABEL)United States1 source record · View provenance
- Species not recorded · SPL section 34070-3 (CONTRAINDICATIONS SECTION) · United States · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Precautions7
Dogs <6 months, cats <4 months; hepatic/cardiac/renal impairment; dehydration/hypovolemia/hypotension; 5–7 day washout recommended before switching NSAIDs in dogs
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Contraindications & Warnings table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Never give a second injectable/oral dose to a cat under the US label — this is an explicit FDA/manufacturer warning after post-marketing renal failure/death reports, though low-dose chronic use is accepted practice in feline medicine outside the US label and per ISFM/AAFP consensus guidelines.
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Clinical pearl · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Oral liquid dosed by "drops" — concentration per drop varies by country/product; measure carefully, don't confuse dropper markings with mL/kg.
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Clinical pearl · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
For oral use in dogs only. Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration. Owner should be advised to observe their dog for signs of potential drug toxicity and begiven a client information sheet about OstiLox (meloxicam) Oral Suspension. Keep OstiLox (meloxicam) Oral Suspension in a secure location out of reach of dogs, cats and other animals to prevent accidental ingestion or overdose.
DogOn-label (ON_LABEL)United States1 source record · View provenance
- Dog · SPL section 34071-1 (WARNINGS SECTION) · United States · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
The safe use of OstiLox (meloxicam) Oral Suspensionin dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating dogs has not been evaluated. Meloxicam is not recommended for use in dogs with bleeding disorders, as safety has not been established in dogs with these disorders. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, orthose with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. If additional pain medication is needed after administration of the total daily dose of OstiLox (meloxicam) Oral Suspension, a non-NSAID or non-corticosteroid class of analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from corticosteroid use or from one NSAID to another in dogs. The use of concomitantly protein-bound drugs with OstiLox (meloxicam) Oral Suspensionhas not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of OstiLox (meloxicam) Oral Suspension has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy.
DogOn-label (ON_LABEL)United States1 source record · View provenance
- Dog · SPL section 42232-9 (PRECAUTIONS SECTION) · United States · On-label (ON_LABEL) · Pending clinical review (PROPOSED) · Rule-based
Interactions6
ACE inhibitors — ↓ antihypertensive effect
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Drug Interactions table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Anticoagulants — ↑ bleeding risk
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Drug Interactions table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Aspirin, corticosteroids, other NSAIDs — ↑ GI toxicity
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Drug Interactions table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Digoxin — ↑ digoxin levels
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Drug Interactions table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Fluconazole — Possible ↑ meloxicam levels
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Drug Interactions table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Pharmacokinetics8
Bioavailability — Near-complete PO with food (dog); 85–98% (horse)
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Pharmacokinetics table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Protein binding — ~97%
DogCatNot applicable (NOT_APPLICABLE)2 source records · View provenance
- Dog · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Pharmacokinetics table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
- Cat · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Pharmacokinetics table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Half-life — 24h avg (12–36h range, dog); 15–26h (cat, study-dependent); 8.5h (horse)
DogNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Dog · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Pharmacokinetics table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Metabolism — Extensive hepatic, multiple inactive metabolites
Other speciesNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Other species · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Pharmacokinetics table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Elimination — Primarily fecal
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Pharmacokinetics table · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Pregnancy / lactation considerations1
Not established in breeding/pregnant/lactating dogs or cats. Human FDA category C. Most NSAIDs excreted in milk — use cautiously.
Species not recordedNot applicable (NOT_APPLICABLE)1 source record · View provenance
- Species not recorded · Plumb's Veterinary Drug Handbook, 7th ed., p. 779–782; Saunders Handbook of Veterinary Drugs (Papich), 4th ed., p. 488–518 (monograph pages 488–490) — Pregnancy & Lactation · Not applicable · Not applicable (NOT_APPLICABLE) · Pending clinical review (PROPOSED) · Rule-based
Literature references8
References are linked to this drug. Species applicability is not recorded here, so the species filter does not narrow this list. Imported dates do not retain their original precision; confirm dates in the original citation.
- First UV-Based Strategies Integrating Whiteness, Greenness, and Blueness Appraisals for Estimating Meloxicam and Tramadol Concurrently in Their Veterinary Mixture.
Study summary not available in the imported record. Open the original citation to review the study.
- Meloxicam blood levels are not affected by sex-related hormones in male and female goats.
Study summary not available in the imported record. Open the original citation to review the study.
- Use of non-steroidal anti-inflammatory drugs for Finnish sows.
Study summary not available in the imported record. Open the original citation to review the study.
- Perioperative analgesia and clinical safety of dexketoprofen in dogs undergoing ovariohysterectomy.
Study summary not available in the imported record. Open the original citation to review the study.
- The Use of Doramectin Reduces Respiratory Mite Associated Mortality in a Population of Gouldian Finches (Chloebia gouldiae).
Study summary not available in the imported record. Open the original citation to review the study.
Sources: DailyMed, U.S. National Library of Medicine; PubMed, National Library of Medicine; openFDA, U.S. Food and Drug Administration; Plumb DC. Plumb's Veterinary Drug Handbook. 7th ed. PharmaVet Inc; 2011.